Fabry disease
Market Access/ News/ News/ Top stories
Chiesi’s flagship Fabry drug heads for FDA verdict in early 2021
Phil Taylor
Chiesi, Fabry disease, Protalix, rare disease
0 Comment
Chiesi starts rare diseases division, ahead of potential Fabry disease filing
Richard Staines
Chiesi, Fabry disease, Protalix, R&D, Rare diseases, respiratory, Takeda
0 Comment
Amicus’ oral Fabry disease drug approved in US
Richard Staines
Amicus Therapeutics, Fabry disease, FDA approval, Galafold, rare disease
0 Comment
Decision follows approval in Europe
News/ Pharma Market Access/ Sales and Marketing/ UK & Europe
Amicus set for share of Fabry market after NICE approval
Andrew McConaghie
Amicus Therapeutics, Fabry disease, NICE, Rare diseases
0 Comment